Literature DB >> 3301331

Crosses of two independently derived transgenic mice demonstrate functional complementation of the genes encoding heavy (HLA-B27) and light (beta 2-microglobulin) chains of HLA class I antigens.

P Krimpenfort, G Rudenko, F Hochstenbach, D Guessow, A Berns, H Ploegh.   

Abstract

In man a number of diseases are associated with certain alleles of MHC antigens. The most pronounced example is ankylosing spondylitis, which is strongly associated with HLA-B27. As a first step towards a model system to study the basis of this association, transgenic mice were generated that showed cell surface expression of the HLA-B27 antigen biochemically indistinguishable from HLA-B27 antigen expressed on human cells. This result was obtained by crossing two independently derived strains of mice, one of which is transgenic for the HLA-B27 heavy chain gene, and the other carrying and expressing the human beta 2m gene. Examination of HLA-B27 and human beta 2m mRNA in various tissues shows the two genes to be expressed in a coordinate fashion. The mRNA levels follow those of endogenous H-2 Class I genes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3301331      PMCID: PMC553540          DOI: 10.1002/j.1460-2075.1987.tb02416.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  17 in total

1.  An improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes.

Authors:  J J Neefjes; B S Breur-Vriesendorp; G A van Seventer; P Iványi; H L Ploegh
Journal:  Hum Immunol       Date:  1986-06       Impact factor: 2.850

2.  Ankylosing spondylitis and HL-A 27.

Authors:  D A Brewerton; F D Hart; A Nicholls; M Caffrey; D C James; R D Sturrock
Journal:  Lancet       Date:  1973-04-28       Impact factor: 79.321

3.  Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer.

Authors:  A K Sood; D Pereira; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

4.  Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules.

Authors:  H L Ploegh; H T Orr; J L Strominger
Journal:  Cell       Date:  1981-05       Impact factor: 41.582

5.  Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens.

Authors:  F M Brodsky; W F Bodmer; P Parham
Journal:  Eur J Immunol       Date:  1979-07       Impact factor: 5.532

6.  Altered structure of HLA class I heavy chains associated with mouse beta-2 microglobulin.

Authors:  P Ferrier; J C Fontecilla-Camps; D Bucchini; D H Caillol; B R Jordan; F A Lemonnier
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

7.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

Authors:  C Auffray; F Rougeon
Journal:  Eur J Biochem       Date:  1980-06

8.  Gene conversion-like mechanisms may generate polymorphism in human class I genes.

Authors:  G H Seemann; R S Rein; C S Brown; H L Ploegh
Journal:  EMBO J       Date:  1986-03       Impact factor: 11.598

9.  Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations.

Authors:  W M Kast; A M Bronkhorst; L P de Waal; C J Melief
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

10.  Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation.

Authors:  G Selten; H T Cuypers; M Zijlstra; C Melief; A Berns
Journal:  EMBO J       Date:  1984-12-20       Impact factor: 11.598

View more
  20 in total

1.  Animal models of the spondyloarthropathies.

Authors:  M Breban; G Falgarone; H Blanchard; E Dernis-Labous; D Lamarque
Journal:  Curr Rheumatol Rep       Date:  2000-08       Impact factor: 4.592

Review 2.  Expression of nonclassical MHC class Ib genes: comparison of regulatory elements.

Authors:  T Kevin Howcroft; Dinah S Singer
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  Mouse cytotoxic T cells can recognize HLA-B27 antigen without H-2 restriction.

Authors:  A Samaan; D Gillet; M Chopin; L Degos; M Pla
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

4.  Recognition of xeno-(HLA, SLA) major histocompatibility complex antigens by mouse cytotoxic T cells is not H-2 restricted: a study with transgenic mice.

Authors:  F Kievits; J Wijffels; W Lokhorst; P Ivanyi
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

Review 5.  Reactivity between monoclonal anti-HLA-B27 antibodies and bacterial components: is there a consensus of findings?

Authors:  M N Ren; J J Zhang; A Nakayama; D T Yu
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

6.  Transgenic rescue implicates beta2-microglobulin as a diabetes susceptibility gene in nonobese diabetic (NOD) mice.

Authors:  E E Hamilton-Williams; D V Serreze; B Charlton; E A Johnson; M P Marron; A Mullbacher; R M Slattery
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

7.  Hierarchy in the assembly of HLA-B27 and HLA-Cw3 molecules in transgenic mice.

Authors:  S Pedrinaci; J Hanson; C David
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

8.  The absence of human beta 2-microglobulin increases the occurrence of ankylosing enthesopathy in HLA-B27 transgenic mice.

Authors:  M Chopin; R Plichtova; B Urbero; M Pla
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

9.  Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.

Authors:  Gabriele Proetzel; Derry C Roopenian
Journal:  Methods       Date:  2013-07-16       Impact factor: 3.608

10.  Expression of HLA-B27 in transgenic mice is controlled by gene(s) mapping between H-2D and H-2L loci.

Authors:  C L Nickerson-Nutter; K L Hogen; C S David
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.